Two from UK join Caligor Rx in US

Will lead quality assurance and clinical trial supplies

Caligor Rx, a global clinical trial procurement company based in New York, US, has appointed Jess McKenna as head of quality assurance and customer relationships and Jacquelyn May as head of clinical trial supplies. The two women join Caligor Rx, as a team, after having spent five years working together for a UK supplier of clinical trial supplies.

McKenna has a first class degree in Health and Social Care from the Open University in the UK. She was most recently responsible for building a quality assurance department at a supplier of comparator drugs.

May is a registered nurse and joins Caligor Rx after five years in comparator procurement for worldwide clinical trials. She was previously a senior manager in the NHS in the UK.

You may also like

Regulatory

Diversis Capital acquires Caligor Rx

Caligor sources and distributes comparator drugs for clinical trials worldwide from the US and UK
Regulatory

Shimadzu launches ALTRACE energy dispersive X-ray fluorescence spectrometer

High-sensitivity analysis and automated measurements for food, environmental, and pharmaceutical inspections
Regulatory

Abzena advances immunogenicity risk assessment in biologic drug development

New white paper explores how early testing helps predict and prevent unwanted immune responses in therapeutic proteins
Regulatory

Immusoft receives FDA Fast Track Designation for ISP-001, a first-in-class engineered B cell therapy for MPS I

Immusoft’s ISP-001, designed to deliver continuous enzyme production through engineered B cells, becomes the first clinical-stage therapy of its kind to receive FDA Fast Track designation
Regulatory

MoonLake Immunotherapeutics faces Securities Class Action after disastrous Phase III trial results

The announcement about the trial results for the product candidate sonelokimab, a highly anticipated treatment for patients with skin disease, saw MoonLake investors' shares fall by about 90%, prompting an investigation into whether or not they were misled
Regulatory

NAD+ supplement claims under scrutiny as Niagen Bioscience wins landmark advertising case

The National Advertising Division (NAD) has ruled against Reus Research over unsupported NAD+ product claims, reinforcing that oral NAD+ ingestion lacks scientific backing and affirming Niagen’s clinically proven approach
Regulatory

Piramal Pharma Solutions awards Riverview and Digwal for patient centricity

Two sites recognised for innovative initiatives that put patients first
Subscribe now